Cell therapy is moving from the laboratory to industrialization. As of 2026, more than 10 CAR-T products have been approved worldwide, and hundreds of stem cell clinical trials are underway. Behind every cell therapy product, a common support system operates quietly: specimen identification and traceability.
In collaboration with multiple cell therapy companies, BradyLAB BRD has found that the importance of specimen labeling in cell therapy is severely underestimated. A label peeling off, a barcode misread, or a confused ID number can mean a product worth hundreds of thousands of yuan scrapped, or even endanger patient safety. This article systematically explains the critical role of LN₂ labels throughout the cell therapy workflow, and BradyLAB BRD's targeted solutions.
Five Special Challenges Cell Therapy Poses for Specimen Labeling
Compared with conventional biobanks, the labeling requirements for cell therapy products differ in several fundamental ways:
Challenge 1: Extreme temperature span throughout the process. An autologous CAR-T cell product goes from apheresis to infusion through temperature zones including: 2–8 °C (transport), -80 °C (intermediate product freezing), -196 °C (finished product storage), and 37 °C (thawing and infusion). BradyLAB BRD's Lab series labels have been validated at every temperature node, ensuring the label does not peel and the barcode does not deform from 2 °C to -196 °C throughout the process.
Challenge 2: Extremely high regulatory compliance requirements. Cell therapy products are subject to dual regulation under GTP (Good Tissue Practice) and GMP. FDA 21 CFR Part 1271 and EMA ATMP regulations both explicitly require cell therapy products to have full "donor-to-recipient" traceable identification. BradyLAB BRD labels, combined with the ISBT 128 coding standard, meet the compliance requirements of major global regulatory authorities for cell therapy labeling.
Challenge 3: Information volume far exceeds conventional specimens. A tube of ordinary research specimen may need only an ID number. But a cell therapy product needs to be labeled with: product name, lot number, patient ID, collection date, manufacturing date, expiry date, cell count, viability, HLA typing results, and more. BradyLAB BRD offers multi-size label solutions—small sizes for direct application to cryovials, large sizes for label pocket slots on product bags—ensuring all necessary information is clearly presented.
Challenge 4: Multi-person, multi-step operational chain. Cell therapy product identification information needs to be read and verified by multiple roles: collection nurses, logistics personnel, manufacturing technicians, QC personnel, clinical nurses, and others. A read failure at any step can interrupt the entire process. BradyLAB BRD labels have been compatibility-tested with all major brand scanners (Zebra, Honeywell, Datalogic, etc.), ensuring seamless reading across departments and devices.
Challenge 5: Zero-tolerance safety bottom line. A labeling error on a research specimen costs a repeated experiment. A labeling error on a cell therapy product could mean a patient receives the wrong cell product—this must never happen. BradyLAB BRD therefore provides a triple-verification identification solution: 1D barcode (fast scanning) + Data Matrix 2D code (high-density error correction) + human-readable code (manual verification). Cross-verification of the three reduces the probability of identification errors to below 10^-9.
Label Application Scenarios Across the Cell Therapy Workflow
Collection step. Labels on apheresis blood bags must withstand condensation and friction during 2–8 °C cold-chain transport. BradyLAB BRD's Lab series labels offer excellent adhesion to moist surfaces; even with condensation on the blood bag surface, the label remains firmly attached. The ISBT 128 donation number on the label is the starting point of the entire traceability chain.
Manufacturing step. Cell separation, activation, transduction, expansion, and other steps involve multiple intermediate containers—microcentrifuge tubes, culture flasks, culture bags. Each container requires accurate labeling. BradyLAB BRD provides fully compatible label solutions from low to high temperatures: Lab series (-196 °C to +120 °C), covering the full temperature range from LN₂ freezing to 37 °C culture. A batch of CAR-T products may require 20–30 labels of different sizes during manufacturing. BradyLAB BRD simplifies consumable management and equipment configuration through standardized label specifications (uniformly using PET face stock + resin ribbon printing).
QC release step. Release testing includes sterility testing, endotoxin testing, mycoplasma testing, cell viability, transduction efficiency, CAR expression rate, and more. The ID number of each test sample must strictly correspond to the main product batch. BradyLAB BRD recommends a parent-child numbering system—the main product uses the full number, and child samples append a test item code after the parent number, ensuring traceability while avoiding confusion. Implementing this coding system relies on BradyLAB BRD labels' high information density printing capability.
Finished product storage step. Cell therapy finished products are typically stored long-term in LN₂ vapor phase (approximately -150 °C to -190 °C). BradyLAB BRD's Lab series labels have undergone more than 500 freeze–thaw cycle tests (see article ID:35), with barcode readability retention exceeding 99%. In addition, BradyLAB BRD labels support RFID function extension—integrating a UHF RFID inlay on the back of the label enables batch inventory and locating without opening the LN₂ tank.
Transport and distribution step. Transport of cell therapy products from the manufacturing center to the clinical point of use typically uses dry shippers, with temperature maintained below -150 °C. BradyLAB BRD labels remain stable under vibration and impact during transport; the edge-reinforced design (Edge-Lock technology) increases peel resistance by 40%.
Infusion verification step. This is the final checkpoint in the safety chain. Nurses use handheld PDAs at the bedside to scan the product label; the system automatically matches patient wristband information, confirming "the right product for the right patient." BradyLAB BRD labels' matte surface treatment ensures clear reading by handheld devices at any lighting angle, with no scan failures even during rushed operations in emergency scenarios.
Compliance Advantages of BradyLAB BRD Cell Therapy Label Solutions
Against the backdrop of tightening global cell therapy regulation, BradyLAB BRD's label solutions offer the following compliance advantages:
ISBT 128 standard compatibility. ISBT 128 is the universal identification standard for cell therapy and transfusion medicine worldwide. BradyLAB BRD labels support ISBT 128's Code 128 barcode format and Data Matrix 2D code format, fully carrying standard fields such as Donation Identification Number (DIN), product code, ABO/Rh blood type, and expiry date. Barcode printing accuracy reaches ANSI Grade B or better, meeting ISBT 128's strict requirements for barcode quality.
21 CFR Part 11 electronic records compliance. BradyLAB BRD's label printing system supports a complete audit trail—every label print is recorded with a timestamp, operator ID, and hash value of the printed content. This meets the FDA's ALCOA+ principles for electronic records (attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, available).
COC/COA documentation support. BradyLAB BRD provides a Certificate of Analysis (COA) for each label batch, detailing the label's material composition, adhesive type, temperature range, and biocompatibility test reports (ISO 10993). A Certificate of Conformance (COC) is also provided, certifying that the batch of labels is fully consistent with validated batches in materials and processes. These documents are important supporting materials for GMP audits at cell therapy companies.
Real-World Case: Full-Workflow Application of BradyLAB BRD Labels at a CAR-T Company
A leading domestic CAR-T company (annual capacity 5,000 patient doses) fully switched to the BradyLAB BRD Lab series label solution in 2024 and achieved the following quantified improvements:
- Label-related deviation events dropped from an average of 3.2 per month to 0.3 per month
- Zero finished-product label peeling in LN₂ over 12 months
- First-scan pass rate increased from 91% to 99.2%
- Label consumable costs reduced by approximately 60% compared with imported solutions
- Zero label-related observations in GMP audits
These data demonstrate that a systematically validated domestic label solution can fully surpass imported products in high-standard applications such as cell therapy.
BradyLAB BRD has always stood at the forefront of biomedical industry development. With the rapid industrialization of immune cell therapies such as CAR-T, CAR-NK, TCR-T, and TIL, as well as stem cell therapies such as MSC and iPSC, quality requirements for specimen labeling will only become more demanding. BradyLAB BRD will continue to invest in R&D to provide the cell therapy industry with safer, more reliable, and more cost-effective domestic label solutions.
📞 18015583218 | 🌐 bradylab.com.cn
Featured Products
For the label materials and application scenarios covered in this article, the following BradyLAB (BRD) products are available for selection reference (click to view specifications and request a quote):
- Lab162-629/40x20 biobank cryovial -196 °C LN₂ nylon cryogenic label biological sample bank 18015583218（¥999/roll）
- Lab027-319/50x25MM gloss white/PP synthetic paper cryogenic adhesive biobank cryovial conical tube microcentrifuge tube BRD BradyLAB（Price on request）
- Lab263-319/45x95mm laboratory cryovial microscope slide biobank label cryogenic adhesive BRD BradyLAB（Price on request）
- Lab164-329-3/φ9.53mm biobank cryovial conical tube microcentrifuge tube cap -80 °C cryogenic label BRD BradyLAB（Price on request）
FAQ
Q: What special requirements apply to labels for stem cell and immune cell therapy specimens?
They must withstand long-term LN₂ freezing, support single-sample-level traceability, and the label material should pass biocompatibility-related assessments to avoid contamination risks.
Q: What information do cell therapy specimen labels contain?
They typically contain key information such as patient/donor ID, specimen type, collection and freezing dates, and lot number, carried in a 2D code and supporting full traceability.
Q: Why are label requirements higher for cell therapy?
Cell therapy specimens directly affect patient safety; labeling errors can lead to serious medical incidents, so durability and traceability requirements are the strictest.
Comparison of Label Requirements for Cell Therapy Specimens
| Specimen type | Label requirements | Compliance focus |
|---|---|---|
| Stem cells | LN₂-resistant, long-term traceable | ISO 20387:2018 |
| Immune cells (CAR-T, etc.) | Highest traceability, zero error | GMP + full-process documentation |
Cell therapy specimens directly affect patient safety; labeling errors can lead to serious medical incidents. Their labels must therefore meet the strictest durability and traceability requirements. Full-process scan documentation and double verification are basic requirements of a cell therapy quality system.